According to a report on September 5th, the National Association of Tobacco Outlets (NATO) in the United States stated that Brian King, the Director of the Center for Tobacco Products (CTP) at the FDA, reiterated the agency's previous statement during a tobacco-friendly conference in Colorado. King expressed that the FDA will continue to enforce regulations on the retail end, with a particular focus on products that have not submitted premarket tobacco product applications (PMTA).
He emphasized the current and potentially forthcoming FDA tobacco regulations, underscoring that "after February 15, 2007, the FDA only authorized the sale of 45 tobacco products, including 23 e-cigarette products." He particularly emphasized the continuous strengthening of compliance checks on tobacco retailers, with the FDA consistently focusing its enforcement resources on products that have not submitted PMTA, are subject to a Marketing Denial Order (MDO), and flavored e-cigarettes (excluding tobacco or menthol flavors) that fail to prevent youth appeal.
The speech by Director King highlighted the current tobacco regulations of the FDA and the potential upcoming regulations.
Despite the previous public announcement by the FDA that the agency planned to release the final regulations banning the use of menthol in cigarettes and the addition of flavors in cigars in August of this year, Commissioner King stated that the final regulations are expected to be published by the end of 2023.
The FDA previously announced its plans to release new proposed regulations by the end of 2023 to solicit public opinion on setting a maximum limit for nicotine in cigarettes and other combustible tobacco products. However, Director King stated that the nicotine cap regulations will be published at some point after the FDA releases the final regulations for menthol cigarettes and flavored cigars later this year.
The FDA will continue to conduct compliance checks on retailers to determine if they are selling tobacco and e-cigarette products that have been refused marketing authorization by the agency or are undergoing pre-market review by the FDA without receiving a final refusal or authorization order. The agency has not yet released sales information for these products.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
